PKTX..Announces the formation of a new Structure..
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) announces the formation of a new structure that allows the Company the flexibility of financing through a subsidiary, partnering through a subsidiary or selling the subsidiary. These new entities will contain rights to clearly defined AAGP™ applications that can easily be segregated from the overall asset base.
Due to recent discussions and testing, the first subsidiary to be formed will be for the large (estimated to be $40 to $50-Billion annually worldwide and growing) monoclonal antibody production market. Those rights will have significant value in increasing the productivity of hybridoma cells which make monoclonal antibodies. In one test AAGP™ increased the production of antibodies by 300% and in another test by 500%.
AAGP™ bio assays (which can be viewed at our revised web site) show that AAGP™ has an important role in Regenerative Medicine. Regenerative Medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and is becoming one of the largest growth industries in healthcare.
ProtoKinetix anticipates the requirement to establish several subsidiaries to maximize the financial returns for its shareholders.